Approach to the Evaluation and Management of Interstitial Lung Abnormalities: An Official American Thoracic Society Clinical Statement. Guideline uri icon

Overview

abstract

  • Background: There is growing interest in identifying early stages of interstitial lung disease (ILD) to improve patient outcomes. This document reviews updated evidence on interstitial lung abnormalities (ILAs); provides suggestions for screening, evaluation, and management; proposes criteria for distinguishing ILAs from ILD; and identifies research priorities. Methods: A committee of clinical and methodology experts met by video conference to define ILAs and ILD by consensus and voted on 11 prespecified questions after reviewing synthesized evidence from a systematic literature search. Agreement of ≥70% was required to approve each suggestion. Results: ILA is defined as nondependent bilateral parenchymal abnormalities on computed tomography, including ground-glass opacities or reticulations, lung distortion, traction bronchiectasis, and/or honeycombing involving ≥5% of a lung zone. The updated definition removes the prior exclusion of high-risk populations. ILD is distinguished from ILAs by symptoms (dyspnea/cough) attributable to an interstitial process, abnormal or declining lung function, fibrotic (honeycombing and/or reticulation with traction bronchiectasis involving ≥5% of total lung volume) or progressive imaging abnormalities, and/or specific fibrotic ILD patterns on imaging or pathology. Suggestions include ILA/ILD assessment on imaging acquired for lung cancer screening, screening adults with connective tissue disease and first-degree relatives of patients with familial pulmonary fibrosis, assessing baseline symptoms and pulmonary function among those with ILAs, and monitoring ILAs with chest computed tomography every 2-3 years. Conclusions: This document presents a comprehensive literature review of ILAs with updates to the Fleischner Society ILA definition, establishes a working ILD definition, and provides evidence-based suggestions for ILA evaluation and management.

authors

  • Podolanczuk, Anna
  • Hunninghake, Gary M
  • Wilson, Kevin C
  • Khor, Yet H
  • Kheir, Fayez
  • Pang, Brandon
  • Adegunsoye, Ayodeji
  • Cararie, Gretchen
  • Corte, Tamera J
  • Flanagan, Jim
  • Gudmundsson, Gunnar
  • Hariri, Lida P
  • Hatabu, Hiroto
  • Humphries, Stephen M
  • Kaul, Bhavika
  • Kim, John S
  • Konigshoff, Melanie
  • Kropski, Jonathan A
  • Lee, Joyce S
  • Luo, Fengming
  • Lynch, David A
  • Martinez, Fernando J
  • Montesi, Sydney B
  • Moodley, Yuben
  • Oldham, Justin M
  • Piciucchi, Sara
  • Putman, Rachel K
  • Richeldi, Luca
  • Rosas, Ivan O
  • Salisbury, Margaret L
  • Salvatore, Mary M
  • Selman, Moises
  • Seo, Joon Beom
  • Song, Jin Woo
  • Thomson, Carey C
  • Vivero, Marina
  • Wain, Louise V
  • Wijsenbeek, Marlies
  • Schwartz, David A
  • Ryerson, Christopher J

publication date

  • July 1, 2025

Research

keywords

  • Lung Diseases, Interstitial

Identity

PubMed Central ID

  • PMC12264694

Scopus Document Identifier

  • 105010189387

Digital Object Identifier (DOI)

  • 10.1164/rccm.202505-1054ST

PubMed ID

  • 40387336

Additional Document Info

volume

  • 211

issue

  • 7